StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) shareholders

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3099% above fair value
$170.26+2.68 (+1.60%)

Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
89.8%
1.11B of 1.24B shares
Institutional holders
2,274
152 new, 164 sold out
Net institutional buying
28M
In Q2 2026
Insider trades, 12 months
0 buys · 84 sales
Net sold $103.60M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.101,739,2738.20%13G (passive) amendmentMar 31, 2025
Vanguard Capital Management93,327,1277.51%13G (passive)Mar 31, 2026
FMR LLC
Joint filing with Abigail P. Johnson (5.30%)
65,539,4775.30%13G (passive)Dec 31, 2025
Gilead Sciences, Inc.18,759,46519.40%13G (passive) amendmentDec 20, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GILDValueChange% of portfolio
BlackRock, Inc.121,844,1089.82%$15.39B+2,833,1350.23%
Vanguard Capital Management LLC81,091,7346.54%$10.25B+436,9580.22%
FMR LLC66,870,8165.39%$8.45B−5,035,4740.37%
State Street Corp61,216,5524.94%$7.73B+1,357,9670.23%
Capital World Investors40,988,9753.30%$5.18B−294,9580.61%
Invesco Ltd.39,819,1513.21%$5.03B−1,761,6720.40%
Vanguard Portfolio Management LLC35,316,1682.85%$4.46B+186,7030.20%
Geode Capital Management, LLC30,065,6422.42%$3.80B+339,5900.20%
Price T Rowe Associates Inc /Md/29,996,6942.42%$3.79B+3,748,5860.38%
Morgan Stanley24,004,3541.94%$3.03B+705,0590.16%
Dodge & Cox23,677,5671.91%$2.99B−573,2591.57%
Norges Bank21,965,5551.77%$2.78BNew0.28%
JPMorgan Chase & Co20,820,6211.68%$2.63B−13,171,7890.15%
Capital Research Global Investors19,393,2961.56%$2.45B−7,734,2370.34%
Bank Of America Corp /De/18,649,0651.50%$2.36B−1,329,8710.15%
Bank of New York Mellon Corp15,263,9291.23%$1.93B+210,7780.32%
Northern Trust Corp13,828,0101.11%$1.75B+7,6310.20%
UBS Asset Management Americas Inc12,986,5911.05%$1.64B−212,5120.30%
Wellington Management Group Llp12,699,6831.02%$1.60B−838,3080.28%
Goldman Sachs Group Inc10,778,2940.87%$1.36B−286,9200.12%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20262,2741.11B89.8%152 / 952855 / 16489M61M
Q1 20262,3251.09B87.8%247 / 859897 / 106182M93M
Q4 20252,2191.12B90.6%334 / 879742 / 111130M81M
Q3 20252,0331.08B86.9%166 / 832728 / 12668M70M
Q2 20252,0261.08B87.2%188 / 844732 / 15392M73M
Q1 20252,0181.06B85.8%279 / 690831 / 11291M84M
Q4 20241,8891.07B85.9%291 / 656719 / 9480M62M
Q3 20241,7221.05B84.7%173 / 630697 / 115190M63M
Q2 20241,6811.05B84.3%129 / 650690 / 15058M93M
Q1 20241,7231.08B87.4%139 / 637737 / 17080M66M
Q4 20231,7791.07B86.4%224 / 654696 / 10071M39M
Q3 20231,6851.04B84.0%130 / 686634 / 12638M33M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

1,360 funds held GILD in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GILDValue% of fundAs of
Vanguard Total Stock Market Index Fund39,416,8933.18%$4.98B0.22%Jun 30, 2026
Vanguard 500 Index Fund32,173,7502.59%$4.06B0.24%Jun 30, 2026
Invesco QQQ Trust, Series 126,355,0382.12%$3.33B0.68%Jun 30, 2026
Dodge & Cox Stock Fund17,282,8121.39%$2.18B1.84%Jun 30, 2026
iShares Core S&P 500 ETF17,078,6281.38%$2.16B0.24%Jun 30, 2026
Fidelity 500 Index Fund15,877,0111.28%$2.13B0.26%May 31, 2026
Income Fund of America15,498,5501.25%$2.02B1.36%Jul 31, 2026
Vanguard Value Index Fund11,816,6810.95%$1.49B0.59%Jun 30, 2026
Fidelity Contrafund11,403,5130.92%$1.44B0.80%Jun 30, 2026
Washington Mutual Investors Fund10,310,7270.83%$1.34B0.62%Jul 31, 2026
American Balanced Fund9,637,6600.78%$1.22B0.42%Jun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF8,771,3120.71%$1.11B2.73%Jun 30, 2026
Capital Income Builder8,051,8060.65%$1.05B0.80%Jul 31, 2026
Vanguard Dividend Appreciation Index Fund7,024,7400.57%$914.69M0.70%Jul 31, 2026
Vanguard Institutional Index Fund6,740,1200.54%$851.55M0.24%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Daniel Patrick O'DayChairman & CEO, Director551,6830.04%Nov 6, 2026
Wettan Keeley M. CainEVP Gen Counsel, Legal & Comp5,3600.00%Nov 9, 2026
Andrew D. DickinsonChief Financial Officer161,0960.01%Oct 16, 2026
Johanna MercierChief Comm & Corp Aff Officer113,6840.01%Oct 16, 2026
Erin BurkhartSVP, Controllership2,2230.00%Sep 23, 2026
Dietmar BergerChief Medical Officer19,7850.00%Sep 11, 2026
Deborah H. TelmanEVP, Corporate Affairs & GC79,6410.01%Nov 13, 2025
Diane E. WilfongInterim Corp Controller & CAO46,5970.00%Sep 11, 2025
Sandra PattersonSVP, Controllership40,0770.00%Mar 12, 2025
Merdad ParseyChief Medical Officer84,6210.01%Dec 11, 2024
Kelly A. KramerDirector1,3390.00%Nov 16, 2026
Anthony WeltersDirector20,6120.00%Aug 27, 2026
Jeffrey BluestoneDirector10,0660.00%Aug 21, 2026
Jacqueline K. BartonDirector27,2020.00%May 4, 2026
Javier RodriguezDirector13,3640.00%May 4, 2026
Sandra HorningDirector6,2930.00%May 4, 2026
Ted W. LoveDirector5,4840.00%May 4, 2026
Harish ManwaniDirector15,0150.00%May 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Kelly A. Kramer
Director
Nov 12, 2026Sale(10b5-1 plan)−200$171.44$34.29K1,339
Kelly A. Kramer
Director
Nov 12, 2026Sale(10b5-1 plan)−4,700$170.49$801.32K1,539
Kelly A. Kramer
Director
Nov 12, 2026Sale(10b5-1 plan)−3,800$169.44$643.88K6,239
Kelly A. Kramer
Director
Nov 12, 2026Sale(10b5-1 plan)−1,676$168.23$281.95K10,039
Kelly A. Kramer
Director
Nov 12, 2026Option exercise+10,376$66.92$694.36K11,715
Wettan Keeley M. Cain
EVP Gen Counsel, Legal & Comp
Nov 6, 2026Sale(10b5-1 plan)−3,399$164.11$557.81K5,360
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 5, 2026Sale(10b5-1 plan)−9,810$175.17$1.72M551,683
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 5, 2026Option exercise+9,810$72.34$709.66K561,493
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 4, 2026Sale(10b5-1 plan)−102,619$175.16$17.98M551,683
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 4, 2026Option exercise+102,619$72.34$7.42M654,302
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−2,000$171.06$342.13K551,683
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−7,796$170.35$1.33M553,683
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−1,904$169.27$322.30K561,479
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−1,700$168.10$285.77K563,383
Daniel Patrick O'Day
Chairman & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−1,600$167.40$267.84K565,083
Daniel Patrick O'Day
Chairman & CEO, Director
Oct 30, 2026Sale(10b5-1 plan)−15,881$175.25$2.78M566,683
Daniel Patrick O'Day
Chairman & CEO, Director
Oct 30, 2026Option exercise+15,881$72.34$1.15M582,564
Johanna Mercier
Chief Comm & Corp Aff Officer
Oct 15, 2026Sale(10b5-1 plan)−3,000$156.22$468.66K113,684
Andrew D. Dickinson
Chief Financial Officer
Oct 15, 2026Sale(10b5-1 plan)−3,000$156.22$468.66K161,096
Daniel Patrick O'Day
Chairman & CEO, Director
Oct 1, 2026Sale(10b5-1 plan)−3,000$148.63$445.88K566,683
Daniel Patrick O'Day
Chairman & CEO, Director
Oct 1, 2026Sale(10b5-1 plan)−12,000$147.72$1.77M569,683
Erin Burkhart
SVP, Controllership
Sep 22, 2026Option exercise+2,223––2,223
Erin Burkhart
SVP, Controllership
Sep 22, 2026Tax withholding−768$152.67$117.25K1,455
Johanna Mercier
Chief Comm & Corp Aff Officer
Sep 15, 2026Sale(10b5-1 plan)−600$145.29$87.17K116,684
Johanna Mercier
Chief Comm & Corp Aff Officer
Sep 15, 2026Sale(10b5-1 plan)−800$144.46$115.57K117,284
Johanna Mercier
Chief Comm & Corp Aff Officer
Sep 15, 2026Sale(10b5-1 plan)−1,600$143.69$229.90K118,084
Andrew D. Dickinson
Chief Financial Officer
Sep 15, 2026Sale(10b5-1 plan)−3,000$145.29$435.87K164,096
Dietmar Berger
Chief Medical Officer
Sep 10, 2026Option exercise+533––19,785
Dietmar Berger
Chief Medical Officer
Sep 10, 2026Tax withholding−263$144.81$38.09K19,522
Daniel Patrick O'Day
Chairman & CEO, Director
Sep 10, 2026Option exercise+8,780––585,913
Daniel Patrick O'Day
Chairman & CEO, Director
Sep 10, 2026Tax withholding−4,230$144.81$612.55K581,683
Wettan Keeley M. Cain
EVP Gen Counsel, Legal & Comp
Sep 10, 2026Tax withholding−285$144.81$41.27K8,759
Wettan Keeley M. Cain
EVP Gen Counsel, Legal & Comp
Sep 10, 2026Option exercise+590––9,044
Andrew D. Dickinson
Chief Financial Officer
Sep 10, 2026Option exercise+2,797––168,443
Andrew D. Dickinson
Chief Financial Officer
Sep 10, 2026Tax withholding−1,347$144.81$195.06K167,096
Johanna Mercier
Chief Comm & Corp Aff Officer
Sep 10, 2026Tax withholding−1,347$144.81$195.06K119,684
Johanna Mercier
Chief Comm & Corp Aff Officer
Sep 10, 2026Option exercise+2,797––121,031
Daniel Patrick O'Day
Chairman & CEO, Director
Sep 1, 2026Sale(10b5-1 plan)−5,408$149.38$807.85K577,133
Daniel Patrick O'Day
Chairman & CEO, Director
Sep 1, 2026Sale(10b5-1 plan)−7,992$148.36$1.19M582,541
Daniel Patrick O'Day
Chairman & CEO, Director
Sep 1, 2026Sale(10b5-1 plan)−1,600$147.51$236.02K590,533
Anthony Welters
Director
Aug 26, 2026Option exercise+7,718$60.67$468.25K20,612
Anthony Welters
Director
Aug 26, 2026Option exercise+10,282$61.35$630.80K23,176
Anthony Welters
Director
Aug 26, 2026Sale(10b5-1 plan)−3,118$148.31$462.43K17,494
Anthony Welters
Director
Aug 26, 2026Sale(10b5-1 plan)−3,402$148.24$504.31K19,774
Anthony Welters
Director
Aug 26, 2026Sale(10b5-1 plan)−6,880$148.82$1.02M12,894
Anthony Welters
Director
Aug 26, 2026Sale(10b5-1 plan)−4,600$148.82$684.57K12,894
Jeffrey Bluestone
Director
Aug 20, 2026Sale(10b5-1 plan)−26$146.36$3.81K10,066
Jeffrey Bluestone
Director
Aug 20, 2026Option exercise+335$61.35$20.55K10,401
Jeffrey Bluestone
Director
Aug 20, 2026Sale(10b5-1 plan)−335$146.26$49.00K10,066
Jeffrey Bluestone
Director
Aug 20, 2026Option exercise+1,816$67.45$122.49K11,882
Jeffrey Bluestone
Director
Aug 20, 2026Sale(10b5-1 plan)−1,165$143.75$167.47K10,066
Jeffrey Bluestone
Director
Aug 20, 2026Option exercise+1,165$67.45$78.58K11,231
Jeffrey Bluestone
Director
Aug 20, 2026Sale(10b5-1 plan)−1,816$144.92$263.17K10,066
Jeffrey Bluestone
Director
Aug 20, 2026Option exercise+26$67.45$1.75K10,092
Jeffrey Bluestone
Director
Aug 20, 2026Sale(10b5-1 plan)−1,658$145.73$241.62K10,066
Jeffrey Bluestone
Director
Aug 20, 2026Option exercise+1,658$67.45$111.83K11,724
Johanna Mercier
Chief Comm & Corp Aff Officer
Aug 17, 2026Option exercise+23,110$66.64$1.54M144,344
Johanna Mercier
Chief Comm & Corp Aff Officer
Aug 17, 2026Option exercise+1,890$72.34$136.72K146,234
Johanna Mercier
Chief Comm & Corp Aff Officer
Aug 17, 2026Sale(10b5-1 plan)−16,530$137.37$2.27M129,704
Johanna Mercier
Chief Comm & Corp Aff Officer
Aug 17, 2026Sale(10b5-1 plan)−11,470$138.04$1.58M118,234

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.72%
21M shares short
Days to cover
3.2
At 7M shares a day
Change since last report
+4.9%
From 20M shares
Short volume, 20 days
45.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gilead Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 81,355 shares on Oct 9, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Wettan Keeley M. Cain
Officer
Nov 6, 20263,399$569.57KNov 6, 2026Restricted Stock Units
Daniel Patrick O'Day
Director, Officer
Nov 4, 2026112,429$18.83MNov 4, 2026Exercise of Stock Options
Daniel Patrick O'Day
Director, Officer
Oct 30, 202645,881$7.60MOct 30, 2026Exercise of Stock Options
Andrew D. Dickinson
Officer
Oct 15, 20263,000$468.66KOct 15, 2026Performance Shares
Johanna Mercier
Officer
Oct 15, 20263,000$468.66KOct 15, 2026Performance Shares
Andrew D. Dickinson
Officer
Sep 15, 20263,000$435.87KSep 15, 2026Performance Shares
Johanna Mercier
Officer
Sep 15, 20263,000$432.65KSep 15, 2026Performance Shares
Anthony Welters
Director
Aug 26, 202618,000$2.68MAug 26, 2026Exercise of Stock Options
Jeffrey Bluestone
Director
Aug 20, 20265,000$738.00KAug 20, 2026Exercise of Stock Options
Johanna Mercier
Officer
Aug 17, 202628,000$3.85MAug 17, 2026Stock Option Exercise
Andrew D. Dickinson
Officer
Aug 17, 20263,000$415.08KAug 17, 2026Performance Shares
Daniel Patrick O'Day
Director, Officer
Aug 3, 202655,000$7.16MAug 3, 2026Restricted Stock Units and Performance Stock Units
Andrew D. Dickinson
Officer
Jul 15, 20263,000$389.78KJul 15, 2026Performance Shares
Johanna Mercier
Officer
Jul 15, 20263,000$389.76KJul 15, 2026Performance Shares
Johanna Mercier
Officer
Jun 15, 20263,000$371.76KJun 15, 2026Performance Shares

Congress trades

40 trades in Gilead Sciences reported by 19 members of the House

MemberTypeTradedAmountFiled
Jared Moskowitz
FL23
BoughtMay 6, 2026$1K–15KJun 19, 2026
Jared Moskowitz
FL23 · child
BoughtMay 6, 2026$1K–15KJun 19, 2026
Josh Gottheimer
NJ05 · joint account
BoughtJan 27, 2026$1K–15KFeb 26, 2026
Valerie Hoyle
OR04 · spouse
SoldSep 23, 2025$1K–15KOct 10, 2025
Marjorie Taylor Greene
GA14
BoughtJun 6, 2025$1K–15KJun 18, 2025
Josh Gottheimer
NJ05 · joint account
SoldMay 14, 2025$1K–15KJun 11, 2025
Jefferson Shreve
IN06
SoldMay 12, 2025$15K–50KJun 22, 2025
Marjorie Taylor Greene
GA14
BoughtMay 5, 2025$1K–15KMay 6, 2025
Marjorie Taylor Greene
GA14
BoughtMay 5, 2025$1K–15KMay 6, 2025
Jefferson Shreve
IN06
BoughtMar 31, 2025$15K–50KApr 11, 2025
Carol Devine Miller
WV01
BoughtMar 10, 2025$1K–15KApr 11, 2025
Josh Gottheimer
NJ05 · joint account
BoughtMar 7, 2025$1K–15KApr 10, 2025
Marjorie Taylor Mrs Greene
GA14
BoughtDec 24, 2024$1K–15KDec 27, 2024
Valerie Hoyle
OR04 · spouse
BoughtOct 29, 2024$1K–15KSep 12, 2025
318 days late
Greg Stanton
AZ04 · spouse
SoldOct 24, 2023$1K–15KNov 9, 2023
Greg Stanton
AZ04 · spouse
BoughtSep 26, 2023$1K–15KNov 9, 2023
Daniel Goldman
NY10
SoldJul 12, 2023$15K–50KAug 13, 2023
Zoe Lofgren
CA18 · spouse
SoldMay 25, 2023$1K–15KJun 6, 2023
Daniel Goldman
NY10
BoughtMar 6, 2023$15K–50KApr 17, 2023
Zoe Lofgren
CA18 · spouse
BoughtSep 9, 2022$1K–15KOct 11, 2022
Carol Devine Miller
WV01 · spouse
Sold (part)Nov 10, 2021$15K–50KSep 2, 2022
296 days late
Sara Jacobs
CA51
SoldApr 9, 2021$15KMay 28, 2021
49 days late
Marjorie Taylor Greene
GA14 · joint account
BoughtJan 21, 2021$1K–15KFeb 19, 2021
Gilbert Cisneros
CA31
SoldDec 22, 2020$1K–15KJan 11, 2021
Dean Phillips
MN03
Sold (part)Dec 18, 2020$1K–15KJan 9, 2021
Dean Phillips
MN03
BoughtSep 23, 2020$1K–15KOct 9, 2020
Ed Perlmutter
CO07 · spouse
Sold (part)Sep 1, 2020$1K–15KNov 11, 2020
71 days late
Ed Perlmutter
CO07 · spouse
BoughtJul 15, 2020$1K–15KSep 29, 2020
76 days late
William R. Timmons IV
SC04 · spouse
SoldJun 29, 2020$1K–15KAug 7, 2020
Roger W. Marshall
KS01 · child
BoughtMay 7, 2020$1K–15KJun 3, 2020
Roger W. Marshall
KS01 · child
BoughtMay 5, 2020$1K–15KJun 3, 2020
Roger W. Marshall
KS01 · child
BoughtMay 4, 2020$1K–15KJun 3, 2020
Gilbert Cisneros
CA31
BoughtMar 18, 2020$1K–15KApr 16, 2020
Mikie Sherrill
NJ11
SoldFeb 20, 2020$1K–15KApr 5, 2020
Gilbert Cisneros
CA31
BoughtFeb 7, 2020$1K–15KMar 10, 2020
Mikie Sherrill
NJ11
BoughtJan 21, 2020$1K–15KFeb 19, 2020
Mikie Sherrill
NJ11
SoldDec 18, 2019$1K–15KJan 10, 2020
Earl Blumenauer
OR03
BoughtOct 25, 2019$1K–15KNov 13, 2019
Bill Flores
TX17
BoughtSep 19, 2019$1K–15KOct 7, 2019
Dean Phillips
MN03
Sold (part)May 13, 2019$1K–15KJun 13, 2019

See a number that looks wrong?